Answers are grounded in this paper and cite their sources.
Demonstrates symptom relief and tumor shrinkage in advanced lung cancer following bronchial artery perfusion with HN2, suggesting potential palliative benefit.
Twenty-one patients with advanced lung cancer, limited to the chest, were treated by bronchial artery perfusion using 0.4 to 0.6 mg/kg of HN2 using a double lumen, double balloon aortic catheter. The infusion was made into the aorta between levels T4 and T8. Two patients were infused 2 times. There were no serious complications in these 21 patients. Average survival of the 21 treated patients was 8 months with a range from one day to 45 months. Symptoms were improved in the majority of treated patients. Cough was improved in 80%. Pain was completely relieved in 3, almost completely relieved in 2, and improved in 4–a total 9 of the 15 patients with severe, persistent pain. There was objective evidence of improvement in 12 patients. Five had objective measured improvement in pulmonary function and, in 7 of the 21 patients (32%), there was decrease in the size of the tumor mass as recorded on official x-ray reports. Average survival in 6 patients considered for perfusion but not completed, because of technical difficulties, was 1.8 months with a range from 1 to 3 months.
No takes yet. Share an insight, caveat, or question.
Eugene E. Cliffton (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: